| P50 | author | Jean-Michel Pawlotsky | Q28322422 |
| P2093 | author name string | Jean-Michel Pawlotsky | |
| P2860 | cites work | Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients | Q28375088 |
| | YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection | Q33853661 |
| | Management of hepatitis B: 2000--summary of a workshop | Q34263265 |
| | Molecular diagnosis of viral hepatitis | Q34642858 |
| | Kinetics of acute hepatitis B virus infection in humans. | Q36369106 |
| | A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 |
| | Dynamics of hepatitis B virus infection in vivo | Q42547404 |
| | Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants | Q43504458 |
| | 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. | Q43566428 |
| | Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study | Q43599844 |
| | Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort | Q43693290 |
| | Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers | Q43954106 |
| | Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. | Q44036843 |
| | The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine | Q44071057 |
| | Serum HBV-DNA levels in inactive hepatitis B virus carriers. | Q44655641 |
| | Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro | Q44820781 |
| | Second-generation Hybrid capture test and Amplicor monitor test generate highly correlated hepatitis B virus DNA levels. | Q45736272 |
| | An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques | Q45737487 |
| | Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays | Q45743874 |
| | Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation | Q45748740 |
| | Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy | Q45749250 |
| | Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays | Q45752261 |
| | Quantitative detection of hepatitis B virus DNA in serum using chemiluminescence: comparison with radioactive solution hybridization assay | Q45784569 |
| | Detection and quantitation of hepatitis B virus DNA: comparison of two commercial hybridization assays with polymerase chain reaction | Q45790377 |
| | Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. | Q52076054 |
| | Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. | Q53933482 |
| | Long-term therapy of chronic hepatitis B with lamivudine. | Q54035757 |
| | Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. | Q54386002 |
| | LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION | Q58236604 |
| | PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN | Q58236629 |
| | What technique should be used for routine detection and quantification of HBV DNA in clinical samples? | Q58325059 |
| | A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group | Q68524263 |
| | A preliminary trial of lamivudine for chronic hepatitis B infection | Q71523548 |
| | Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay | Q71774797 |
| | Clinical implications of lamivudine resistance by HBV | Q71955732 |
| | Lamivudine as initial treatment for chronic hepatitis B in the United States | Q73098368 |
| | Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B | Q73308069 |
| | Clinical utility in quantifying serum HBV DNA levels using PCR assays | Q77908549 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| | hepatitis B | Q6853 |
| P304 | page(s) | S31-5 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics | |
| P478 | volume | 39 Suppl 1 | |